Compare Amgen, Inc. (AMGN) vs Manchester United PLC (MANU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Manchester United PLC — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Manchester United PLC trades at $22.28 (market cap $3.80B). The key difference: Amgen, Inc. is far larger — about 51.6× Manchester United PLC's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | MANU | |
|---|---|---|
Market Cap | $196.12B | $3.80B |
Sector | Health | Media |
52-Week High | $388.16 | $23.53 |
52-Week Low | $271.18 | $15.10 |
Enterprise Value | $241.41B | $4.72B |
Dividend Yield | 2.77% | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Manchester United (MANU) trades at $22.04, up 0.18% today, with a bullish technical signal and positive news flow around stadium development. The company reported mixed quarterly earnings but achieved Champions League qualification, boosting future revenue prospects. However, fundamentals show persistent net losses and negative ROE, with a high P/B ratio of 16.05 indicating premium valuation despite profitability challenges.
The outlook is cautiously optimistic, driven by stadium expansion plans and improved sporting performance, but significant execution risks and ongoing financial losses warrant careful monitoring. Analyst sentiment is mixed with 40% buy ratings, reflecting the balance between growth potential and current weak profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →
